Telsey Advisory Group analyst Joseph Feldman maintains Arhaus (NASDAQ:ARHS) with a Outperform and raises the price target from $12 to $14.
Eli Lilly’s Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Goundbreaking results in treating obstructive sleep apnea (OSA) with Eli Lilly's tirzepatide. See significant reductions in apnea-hypopnea index (AHI) and body weight, offering hope for OSA patients.
